Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Ann Clin Biochem ; 46(Pt 1): 24-32, 2009 Jan.
Article in English | MEDLINE | ID: mdl-19028807

ABSTRACT

BACKGROUND: Family tracing is a method recognized to find new patients with familial hypercholesterolaemia (FH). We have implemented family tracing led by FH Nurses and have determined acceptability to patients, feasibility and costs. METHODS: Nurses were located at five National Health Service (NHS) Trusts; they identified FH patients and offered them family tracing. Responses and test results were recorded on a database and summarized on a family pedigree. RESULTS: The majority ( approximately 70%) of index cases participated; the proportion was lower when patients had been discharged from the clinics and in metropolitan areas. On average, 34% (range 13-50%) of relatives lived outside the catchment area of the clinics and could not attend the nurse-led FH clinics. Of the previously untested relatives, 76% who lived in the catchment area of the clinic came forward to be tested. One-third of the relatives who came forward for testing were children

Subject(s)
Hyperlipoproteinemia Type II/diagnosis , Mass Screening/economics , Mass Screening/methods , Medical Audit/economics , Medical Audit/methods , Pilot Projects , Adolescent , Adult , Child , Child, Preschool , Cost-Benefit Analysis , Female , Humans , Hyperlipoproteinemia Type II/epidemiology , Male , Middle Aged , Pedigree , United Kingdom , Young Adult
2.
Ann Clin Biochem ; 45(Pt 2): 199-205, 2008 Mar.
Article in English | MEDLINE | ID: mdl-18325186

ABSTRACT

BACKGROUND: Familial hypercholesterolaemia (FH) is an autosomal co-dominant disorder which is relatively common, leads to high levels of LDL-cholesterol and if untreated to early coronary heart disease. An audit of current practice at National Health Service Trusts in England was undertaken to determine whether FH patients meet the diagnostic criteria for FH; are being offered appropriate advice and treatment; and to what extent their families are contacted and offered testing for the disorder. METHODS: Medical records of known FH patients (over 18 years of age and diagnosed before 31 December 2003) were accessed to obtain information on diagnosis, treatment and family tracing. RESULTS: The records of 733 FH patients were examined, 79% met the UK 'Simon Broome' register criteria for the diagnosis of definite or possible FH. Analyses showed that patients were usually offered appropriate advice and treatment, with 89% being on a statin. However, the audit indicated a high variability in family tracing between the sites, with significant differences in the frequency of inclusion of a family pedigree in the notes (range 1-71%, mean 35%); the general practitioner (GP) being advised that first-degree relatives should be tested (range 4-52%, mean 27%); and the proportion of relatives contacted and tested (range 6-50%, mean 32%). CONCLUSION: FH patients are well cared for in lipid clinics in England, are being given appropriate lifestyle advice and medication, but an increase in recording of LDL-cholesterol levels may lead to improvements in their management. Practice in family tracing appears to vary widely between clinics.


Subject(s)
Hyperlipoproteinemia Type II/diagnosis , Medical Audit , Ambulatory Care Facilities , Cholesterol, LDL/blood , England , Female , Humans , Hyperlipoproteinemia Type II/epidemiology , Hyperlipoproteinemia Type II/therapy , Male , Middle Aged , Patient Education as Topic , Physicians, Family
SELECTION OF CITATIONS
SEARCH DETAIL
...